Gossamer Bio Is A Good Speculative Buy On Seralutinib For PAH And PH-ILD
Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...
Organon & Co. (OGN) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Conference Call February 13, 2025 8:30 AM ETCompany ParticipantsJennifer Halchak - VP, IRKevin Ali - ...
Hosted on MSN13h
Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance
It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc. GILD gained following the earnings beat and upbeat guidance for 2025, ...
Organon targets $1B in Nexplanon revenue for 2025 while advancing Vtama expansion
Q4 2024 Management View CEO Kevin Ali highlighted full-year 2024 revenue of $6.4 billion, representing a 3% growth rate at constant currency. All three franchises posted three consecutive years of ...
Morningstar21h
SFDR Article 8 and Article 9 Funds: Q4 2024 in Review
In Q4 of 2024, Article 8 funds netted an estimated EUR 51.9 billion of net new money, the highest inflows of the year, supported by increased subscriptions into fixed-income funds. This report ...